Onco-Innovations Limited
Onco-Innovations Limited
Your view on ONCO.NE
Overview
What the company does, where it operates, and who runs it.
About Onco-Innovations Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas O'Shaughnessy
- Headquarters
- 7th Street SW, Calgary, AB, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas O'Shaughnessy
- Headquarters
- 7th Street SW, Calgary, AB, CA
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company's lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3'-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. The company has a strategic collaboration with Nucro-Technics Inc. for the development of bioanalytical methods to support preclinical pharmacokinetic and biodistribution studies. Onco-Innovations Limited is headquartered in Calgary, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Onco-Innovations Limited, and the rating behind it. ONCO.NE last traded at C$0.65; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Onco-Innovations Limited. Starting points for Onco-Innovations Limited: EPS -C$0.22, beta 1.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Onco-Innovations Limited. Onco-Innovations Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Onco-Innovations Limited. Trailing twelve-month EPS for Onco-Innovations Limited stands at -C$0.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Onco-Innovations Limited. Onco-Innovations Limited has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Onco-Innovations Limited valued side by side against its closest peers. Onco-Innovations Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Onco-Innovations Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Onco-Innovations Limited executives and directors. Shares of Onco-Innovations Limited have traded between C$0.50 and C$1.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Onco-Innovations Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Onco-Innovations Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Onco-Innovations Limited. Coverage tracks Onco-Innovations Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.